Table 4.
Univariate and multivariate analyses of the association between various clinical characteristics and OS in the COPD group.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HRadj (95% CI) | P value | |
| Age, < 75 years | 0.89 (0.56–1.45) | 0.63 | 1.16 (0.68–1.97) | 0.59 |
| Sex, male | 0.94 (0.48–2.11) | 0.86 | 1.14 (0.52–2.50) | 0.75 |
| Recurrence | 0.49 (0.30–0.78) | 0.0037 | 0.45 (0.27–0.76) | 0.0017 |
| Chemotherapy | ||||
| Platinum doublet | 0.79 (0.52–1.20) | 0.26 | 0.76 (0.48–1.23) | 0.27 |
| TKI | 0.94 (0.60–1.45) | 0.79 | 0.76 (0.47–1.23) | 0.25 |
| %FEV1 < 80% | 1.48 (0.92–2.47) | 0.12 | 2.63 (1.53–4.70) | 0.0007 |
| Performance status, ≥ 2 | 2.96 (1.51–5.31) | 0.0006 | 2.79 (1.40–5.57) | 0.0037 |
| COPD treatment, yes | 0.60 (0.38–0.93) | 0.0243 | 0.52 (0.31–0.87) | 0.0134 |
Comparisons were made by means of chi-squared tests unless otherwise indicated.
Significant values are in [italics].
TKI Tyrosine kinase inhibitors, FEV1 forced expiratory volume in 1 s.